Natera, Inc. (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 1,196 Shares

by · The Cerbat Gem

Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider Solomon Moshkevich sold 1,196 shares of the stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $118.21, for a total transaction of $141,379.16. Following the sale, the insider now directly owns 110,695 shares of the company’s stock, valued at approximately $13,085,255.95. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Solomon Moshkevich also recently made the following trade(s):

  • On Tuesday, October 22nd, Solomon Moshkevich sold 256 shares of Natera stock. The stock was sold at an average price of $120.07, for a total transaction of $30,737.92.

Natera Trading Up 1.6 %

NTRA stock opened at $126.73 on Thursday. Natera, Inc. has a twelve month low of $37.67 and a twelve month high of $133.54. The stock has a market capitalization of $15.67 billion, a price-to-earnings ratio of -51.73 and a beta of 1.53. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The firm’s fifty day simple moving average is $123.31 and its two-hundred day simple moving average is $111.82.

Natera (NASDAQ:NTRA – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.39. The company had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm’s revenue was up 58.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.97) EPS. As a group, analysts anticipate that Natera, Inc. will post -1.96 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have commented on NTRA shares. UBS Group decreased their price target on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. BTIG Research lifted their target price on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Sanford C. Bernstein raised their price target on Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a report on Wednesday. The Goldman Sachs Group lifted their price objective on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Finally, Morgan Stanley increased their target price on Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $125.69.

Get Our Latest Stock Analysis on Natera

Institutional Investors Weigh In On Natera

Several hedge funds and other institutional investors have recently modified their holdings of the business. Itau Unibanco Holding S.A. purchased a new position in Natera during the 2nd quarter valued at $28,000. Quarry LP boosted its stake in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC grew its holdings in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares during the last quarter. Tobam purchased a new position in Natera in the 2nd quarter worth about $74,000. Finally, DekaBank Deutsche Girozentrale bought a new stake in Natera during the 1st quarter valued at about $83,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

See Also